Novel targeted therapies may extend the survival of patients with advanced fallopian tube carcinoma, including poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors, anti-vascular endothelial growth factor (VEGF) antibodies and programmed cell death protein [PD]-1 inhibitors. The gene discussed is VEGFA; the disease is fallopian tube carcinoma.